https://www.selleckchem.com/pr....oducts/elacestrant.h
8%) of whom were using systemic BB. BB use was associated with less frequent SDAI remission in the total [adjusted hazard ratio (HR) 0.70, 95% confidence interval (CI) 0.57-0.87, = 0.001] and CVD cohort [adjusted HR 0.72 (0.57-0.90, = 0.005)]. The association was consistent between trials (interaction = 0.44) and treatment arms (interaction = 0.06). No significant association between remission and β1-receptor selectivity was identified ( = 0.16), and the association was independent from other cardiovascular drug use. Similar as
Me gusta
Comentario
Compartir
